Search
for
Sort by
Research 151–180 of 518
- Ritlecitinib in severe alopecia areata: a profile of its use
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- The Role of Janus Kinase Inhibitors in Dermatology
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- 1323 The effects of 3-OH of kaempferol on interfollicular epidermal stem cell fate
- 1324 Impairment of hair-inducing capacity of 3D-cultured human dermal papilla cells by the ablation of STAT5
- 1327 Effect of ginsenoside Rd on dermal epidermal junction in fibroblast
- 1325 Age-dependent loss of the stemness and antimicrobial defense function of dermal fibroblasts is mediated by TGFbeta
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Tofacitinib for the treatment of lichen planopilaris: A case series
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Fibroblast heterogeneity and functions: insights from single-cell sequencing in wound healing, breast cancer, ovarian cancer and melanoma
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- 916 Gynecologic and hormonal comorbidities of scarring alopecia: A retrospective review
- Ritlecitinib: First Approval
- Effect of tofacitinib on the expression of noggin/BMP-4 and hair growth stimulation in mice
- Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Alopecia areata
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm